Citations (102)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
David W. Hein & Lori M. Millner. (2021) Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review. Expert Opinion on Drug Metabolism & Toxicology 17:1, pages 9-21.
Read now
Read now
Oswaldo Hernández-González, Juan José Ortiz-Zamudio, Cristian Jazmín Rodríguez-Pinal, Ildemar Alvarado-Morales, Verónica del Carmen Martínez-Jiménez, Raúl Alejandro Salazar-González, Lourdes Cecilia Correa-González, Rocío Gómez, Diana Patricia Portales-Pérez & Rosa del Carmen Milán-Segovia. (2018) Genetic polymorphisms of arylamine N-acetyltransferases 1 and 2 and the likelihood of developing pediatric acute lymphoblastic leukemia. Leukemia & Lymphoma 59:8, pages 1968-1975.
Read now
Read now
Hassan R. Dhaini, Bassam El Hafi & Assem M. Khamis. (2018) NAT1 genotypic and phenotypic contribution to urinary bladder cancer risk: a systematic review and meta-analysis. Drug Metabolism Reviews 50:2, pages 208-219.
Read now
Read now
Gary Ginsberg, Suryanarayana V Vulimiri, Yu-Sheng Lin, Jayaram Kancherla, Brenda Foos & Babasaheb Sonawane. (2017) A framework and case studies for evaluation of enzyme ontogeny in children’s health risk evaluation. Journal of Toxicology and Environmental Health, Part A 80:10-12, pages 569-593.
Read now
Read now
Cordula Lukas, Silvia Selinski, Hans-Martin Prager, Meinolf Blaszkewicz, Jan G. Hengstler & Klaus Golka. (2017) Occupational bladder cancer: Polymorphisms of xenobiotic metabolizing enzymes, exposures, and prognosis. Journal of Toxicology and Environmental Health, Part A 80:7-8, pages 439-452.
Read now
Read now
Svetlana Höhne, Holger Gerullis, Meinolf Blaszkewicz, Silvia Selinski, Jan G. Hengstler, Thomas Otto & Klaus Golka. (2017) N-acetyltransferase 1*10 genotype in bladder cancer patients. Journal of Toxicology and Environmental Health, Part A 80:7-8, pages 417-422.
Read now
Read now
Nele Van Der Steen, Chiara Caparello, Christian Rolfo, Patrick Pauwels, Godefridus J Peters & Elisa Giovannetti. (2016) New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?. OncoTargets and Therapy 9, pages 6065-6074.
Read now
Read now
Phu N Tran & Samuel J Klempner. (2016) Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer. Lung Cancer: Targets and Therapy 7, pages 91-97.
Read now
Read now
Félix Javier Jiménez-Jiménez, Hortensia Alonso-Navarro, Elena García-Martín & José A.G. Agúndez. (2016) NAT2 polymorphisms and risk for Parkinson’s disease: a systematic review and meta-analysis. Expert Opinion on Drug Metabolism & Toxicology 12:8, pages 937-946.
Read now
Read now
Ursula Gundert-Remy, Ulrike Bernauer, Brunhilde Blömeke, Barbara Döring, Eric Fabian, Carsten Goebel, Stefanie Hessel, Christine Jäckh, Alfonso Lampen, Franz Oesch, Ernst Petzinger, Wolfgang Völkel & Peter H. Roos. (2014) Extrahepatic metabolism at the body's internal–external interfaces. Drug Metabolism Reviews 46:3, pages 291-324.
Read now
Read now
Hassan R. Dhaini & Loulou Kobeissi. (2014) Toxicogenetic Profile and Cancer Risk in Lebanese. Journal of Toxicology and Environmental Health, Part B 17:2, pages 95-125.
Read now
Read now
Johan Bylund, Carl Petersson, Anders Lindgren, Susanne Olofsson & Stefan Czene. (2013) Metabolic profiling of TRPV1 antagonists of the benzothiazole amide series: implications for in vitro genotoxicity assessment. Xenobiotica 43:2, pages 201-210.
Read now
Read now
Klaus Golka, Hermann
C. Roemer, Wobbeke Weistenhöfer, Meinolf Blaszkewicz, Seddik Hammad, Thomas Reckwitz, Dietrich Loehlein, Mark Hartel, Jan
G. Hengstler & Frank Geller. (2012)
N-Acetyltransferase 2 and Glutathione S-Transferase M1 in Colon and Rectal Cancer Cases from an Industrialized Area. Journal of Toxicology and Environmental Health, Part A 75:8-10, pages 572-581.
Read now
Read now
Gary Ginsberg, Kathryn Guyton, Douglas Johns, Jennifer Schimek, Kenneth Angle & Babasaheb Sonawane. (2010) Genetic polymorphism in metabolism and host defense enzymes: Implications for human health risk assessment. Critical Reviews in Toxicology 40:7, pages 575-619.
Read now
Read now
Articles from other publishers (88)
Islamiat Oladipupo, T’shura Ali, David W. Hein, Kelly Pagidas, Henry Bohler, Mark A. Doll, Merry Lynn Mann, Adrienne Gentry, Jasmine L. Chiang, Rebecca C. Pierson, Sashia Torres, Emily Reece & Kira C. Taylor. (2022) Association between cigarette smoking and ovarian reserve among women seeking fertility care. PLOS ONE 17:12, pages e0278998.
Crossref
Crossref
Ibrahim Abayomi Ogunyinka, Yusuf Hassan Wada, Tajudeen Bolajoko, Yusuf Tahir & Kazeem Adeola Oshikoya. (2022) Completion Rates and Hepatotoxicity of Isoniazid Preventive Therapy Among Children Living with HIV/AIDS: Findings and Implications in Northwestern Nigeria. Drugs & Therapy Perspectives 38:10, pages 455-466.
Crossref
Crossref
Bing Chen, Hao-Qiang Shi, Meihua Rose Feng, Xi-Han Wang, Xiao-Mei Cao & Wei-Min Cai. (2022) Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population. Frontiers in Pharmacology 13.
Crossref
Crossref
Veronique Michaud, Lucy I. Darakjian, Pamela Dow & Jacques Turgeon. (2022) Role of Pharmacogenomics in Reducing the Risk of Drug-Related Iatrogenesis. Current Pharmacology Reports 8:2, pages 79-98.
Crossref
Crossref
Carmine S. Leggett, Mark A. Doll, Raúl A. Salazar-González, Mariam R. Habil, John O. Trent & David W. Hein. (2021) Identification and characterization of potent, selective, and efficacious inhibitors of human arylamine N-acetyltransferase 1. Archives of Toxicology 96:2, pages 511-524.
Crossref
Crossref
Lois D. Lehman-McKeeman & Laura E. Armstrong. 2022. Haschek and Rousseaux's Handbook of Toxicologic Pathology. Haschek and Rousseaux's Handbook of Toxicologic Pathology
15
49
.
Alan Talevi & Carolina L. Bellera. 2022. The ADME Encyclopedia. The ADME Encyclopedia
479
485
.
Alan Talevi & Carolina L. Bellera. 2022. The ADME Encyclopedia. The ADME Encyclopedia
394
400
.
Mariana Babayeva, Brigitte Azzi & Zvi G. Loewy. 2022. Pharmacogenomics in Drug Discovery and Development. Pharmacogenomics in Drug Discovery and Development
201
240
.
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
263
292
.
Sotiria Boukouvala, Nafsika Drakomathioulaki, Georgia Papanikolaou, Theodora Tsirka, Charlotte Veyssière, Audrey Sabbagh, Brigitte Crouau-Roy & Giannoulis Fakis. (2021) Functional variability of rhesus macaque (Macaca mulatta) NAT2 gene for drug-metabolising arylamine N-acetyltransferase 2. Biochemical Pharmacology 188, pages 114545.
Crossref
Crossref
Koya Fukunaga, Ken Kato, Takuji Okusaka, Takeo Saito, Masashi Ikeda, Teruhiko Yoshida, Hitoshi Zembutsu, Nakao Iwata & Taisei Mushiroda. (2021) Functional Characterization of the Effects of N-acetyltransferase 2 Alleles on N-acetylation of Eight Drugs and Worldwide Distribution of Substrate-Specific Diversity. Frontiers in Genetics 12.
Crossref
Crossref
A. A. Kachanova, Yu. A. Pimenova, G. N. Shuev, K. A. Akmalova, Zh. A. Sozaeva, N. M. Krasnova, E. A. Grishina & D. A. Sychev. (2021) Study of the Effect of Polymorphic Markers of the NAT2 Gene on the Risk of Adverse Drug Reactions in Patients with Pulmonary Tuberculosis Who Received Isoniazid and Rifampicin. Safety and Risk of Pharmacotherapy 9:1, pages 25-33.
Crossref
Crossref
Carmine S. Leggett, Mark A. Doll, J. Christopher States & David W. Hein. (2020) Acetylation of putative arylamine and alkylaniline carcinogens in immortalized human fibroblasts transfected with rapid and slow acetylator N-acetyltransferase 2 haplotypes. Archives of Toxicology 95:1, pages 311-319.
Crossref
Crossref
Alan Talevi & Carolina Bellera. 2021. The ADME Encyclopedia. The ADME Encyclopedia
1
7
.
Alan Talevi & Carolina L. Bellera. 2021. The ADME Encyclopedia. The ADME Encyclopedia
1
8
.
Zeina N. Al-Mahayri, George P. Patrinos, Sukanya Wattanapokayakit, Nareenart Iemwimangsa, Koya Fukunaga, Taisei Mushiroda, Wasun Chantratita & Bassam R. Ali. (2020) Variation in 100 relevant pharmacogenes among emiratis with insights from understudied populations. Scientific Reports 10:1.
Crossref
Crossref
Ahmed A. Abulfathi, Peter R. Donald, Kim Adams, Elin M. Svensson, Andreas H. Diacon & Helmuth Reuter. (2020) The pharmacokinetics of para‐aminosalicylic acid and its relationship to efficacy and intolerance. British Journal of Clinical Pharmacology 86:11, pages 2123-2132.
Crossref
Crossref
Laura Dhondt, Siska Croubels, Peter De Paepe, Steven C. Wallis, Saurabh Pandey, Jason A. Roberts, Jeffrey Lipman, Pieter De Cock & Mathias Devreese. (2020) Conventional Pig as Animal Model for Human Renal Drug Excretion Processes: Unravelling the Porcine Renal Function by Use of a Cocktail of Exogenous Markers. Frontiers in Pharmacology 11.
Crossref
Crossref
Thuli Mthiyane, James Millard, John Adamson, Yusentha Balakrishna, Cathy Connolly, Andrew Owen, Roxana Rustomjee, Keertan Dheda, Helen McIlleron & Alexander S. Pym. (2020)
N
-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and
N
-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment
. Antimicrobial Agents and Chemotherapy 64:4.
Crossref
Crossref
Sean AinsworthSean Ainsworth. 2020. Neonatal Formulary. Neonatal Formulary.
Arun Radhakrishnan, Gowthamarajan Kuppusamy, Sivasankaran Ponnusankar & Nikhitha K. Shanmukhan. (2019) Pharmacogenomic phase transition from personalized medicine to patient-centric customized delivery. The Pharmacogenomics Journal 20:1, pages 1-18.
Crossref
Crossref
Florence I. Raynaud. 2020. Metabolomics for Biomedical Research. Metabolomics for Biomedical Research
159
199
.
Lianxia Guo, Dong Dong, Tianpeng Zhang & Baojian Wu. 2020. Circadian Pharmacokinetics. Circadian Pharmacokinetics
113
129
.
Scott M. Langevin & Karl T. Kelsey. 2020. Occupational Cancers. Occupational Cancers
21
38
.
Jennifer L. Baker, Daniel Shriner, Amy R. Bentley & Charles N. Rotimi. 2019. The Genetics of African Populations in Health and Disease. The Genetics of African Populations in Health and Disease
95
127
.
Monadil H. Ali, Alian A. Alrasheedy, Dan Kibuule, Mohamed Azmi Hassali, Brian Godman, Mohammed F. Abdelwahab & Raef Y. Abbadi. (2019) Isoniazid acetylation phenotypes in the Sudanese population; findings and implications. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 17, pages 100120.
Crossref
Crossref
Wei-long Zhang, Zhuo-li Zhu, Mei-chang Huang, Ya-Jie Tang, Ya-ling Tang & Xin-hua Liang. (2019) Susceptibility of Multiple Primary Cancers in Patients With Head and Neck Cancer: Nature or Nurture?. Frontiers in Oncology 9.
Crossref
Crossref
Naheed Akhter, Tahira Iqbal, Amer Jamil, Muhammad Akram, Imtiaz Mehmood Tahir & Naveed Munir. (2019) Determination of Arylamine N-Acetyltransferase 2 Acetylation Genotype by PCR and Phenotyping Using Dapsone Through High-Pressure Liquid Chromatography Assay: A Gender Wise Study. Dose-Response 17:2, pages 155932581985553.
Crossref
Crossref
Felix Hammann, Verena Schöning & Jürgen Drewe. (2018) Prediction of clinically relevant drug‐induced liver injury from structure using machine learning. Journal of Applied Toxicology 39:3, pages 412-419.
Crossref
Crossref
Estella Dora Germaine Garessus, Hans Mielke & Ursula Gundert-Remy. (2019) Exposure of Infants to Isoniazid via Breast Milk After Maternal Drug Intake of Recommended Doses Is Clinically Insignificant Irrespective of Metaboliser Status. A Physiologically-Based Pharmacokinetic (PBPK) Modelling Approach to Estimate Drug Exposure of Infants via Breast-Feeding. Frontiers in Pharmacology 10.
Crossref
Crossref
Junji Zhang, Xianzhi Chai, Xiao-Peng He, Hae-Jo Kim, Juyoung Yoon & He Tian. (2019) Fluorogenic probes for disease-relevant enzymes. Chemical Society Reviews 48:2, pages 683-722.
Crossref
Crossref
Saba Kabir & Abdul Rehman. (2018) Carcinogenic potential of arylamine N-acetyltransferase in Asian populations. Journal of Cancer Research and Practice 5:4, pages 131-135.
Crossref
Crossref
David W. Hein, Giannoulis Fakis & Sotiria Boukouvala. (2018) Functional expression of human arylamine N-acetyltransferase NAT1*10 and NAT1*11 alleles. Pharmacogenetics and Genomics 28:10, pages 238-244.
Crossref
Crossref
Recep Dursun, Hatice Gül Dursun, Ayşe Gül Zamani, Mahmut Selman Yıldırım & İlknur Çınar. (2018)
NAT2
Gene Polymorphisms in Turkish Patients with Psoriasis Vulgaris
. BioMed Research International 2018, pages 1-14.
Crossref
Crossref
Jinhua Li, Birget Moe, Yanming Liu & Xing-Fang Li. (2018) Halobenzoquinone-Induced Alteration of Gene Expression Associated with Oxidative Stress Signaling Pathways. Environmental Science & Technology 52:11, pages 6576-6584.
Crossref
Crossref
Joseph D. Tucci, Paul P. Pumuye, Nuala A. Helsby, Daniel T. Barratt, Percy P. Pokeya, Francis Hombhanje & Andrew A. Somogyi. (2018) Pharmacogenomics in Papua New Guineans. Pharmacogenetics and Genomics 28:6, pages 153-164.
Crossref
Crossref
K.K. Wolf & M.F. Paine. 2018. Comprehensive Toxicology. Comprehensive Toxicology
74
98
.
Manjunath P. Pai, Jennifer J. Kiser, Paul O. Gubbins & Keith A. Rodvold. 2018. Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions. Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions
1
13
.
Lucia M. Procopciuc, Gelu Osian & Mihaela Iancu. (2017) N-acetyl transferase 2/environmental factors and their association as a modulating risk factor for sporadic colon and rectal cancer. Journal of Clinical Laboratory Analysis 31:5, pages e22098.
Crossref
Crossref
David W. Hein & Mark A. Doll. (2017) Catalytic properties and heat stabilities of novel recombinant human N-acetyltransferase 2 allozymes support existence of genetic heterogeneity within the slow acetylator phenotype. Archives of Toxicology 91:8, pages 2827-2835.
Crossref
Crossref
N Ben Fredj, R Gam, E Kerkni, A Chaabane, Z Chadly, N Boughattas & K Aouam. (2016) Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients. The Pharmacogenomics Journal 17:4, pages 372-377.
Crossref
Crossref
Peter E. Haroldsen, Zlatko Sisic, Joe Datt, Donald G. Musson & Gary Ingenito. (2017) Acetylator Status Impacts Amifampridine Phosphate (Firdapse™) Pharmacokinetics and Exposure to a Greater Extent Than Renal Function. Clinical Therapeutics 39:7, pages 1360-1370.
Crossref
Crossref
Svante Vikingsson, Ariane Wohlfarth, Mikael Andersson, Henrik Gréen, Markus Roman, Martin Josefsson, Fredrik C Kugelberg & Robert Kronstrand. (2017) Identifying Metabolites of Meclonazepam by High-Resolution Mass Spectrometry Using Human Liver Microsomes, Hepatocytes, a Mouse Model, and Authentic Urine Samples. The AAPS Journal 19:3, pages 736-742.
Crossref
Crossref
Zhilin Luan, Tianlan Lu, Weihua Yue, Sjef Copray & Dai Zhang. (2017) Association between NAT2 polymorphisms and the risk of schizophrenia in a Northern Chinese Han population. Psychiatric Genetics 27:2, pages 71-75.
Crossref
Crossref
Tim Smeets & Florence van Hunsel. (2016) Red-Brown Urine Discolouration in Two Patients Taking Mesalamine. Drug Safety - Case Reports 3:1.
Crossref
Crossref
Pengcheng Wang, Komal Pradhan, Xiao-bo Zhong & Xiaochao Ma. (2016) Isoniazid metabolism and hepatotoxicity. Acta Pharmaceutica Sinica B 6:5, pages 384-392.
Crossref
Crossref
Kathryn Z. Guyton & Michael D. Waters. 2016. Toxicogenomics in Predictive Carcinogenicity. Toxicogenomics in Predictive Carcinogenicity
247
279
.
Kristina K. Wolf, Brandon T. Gufford, Scott J. Brantley, Paul B. Watkins & Mary F. Paine. 2015. Yamada' s Textbook of Gastroenterology. Yamada' s Textbook of Gastroenterology
626
638
.
José L. Lepe-Zúñiga, Luis E. Aguilar-Gómez & Noemí C. Godínez-Téllez. (2015) Metahemoglobinemia adquirida en el recién nacido asociada con benzocaína y paracetamol. Boletín Médico del Hospital Infantil de México 72:4, pages 271-275.
Crossref
Crossref
Urs Duthaler, Jennifer Keiser & Jörg Huwyler. (2015) LC–MS/MS method for the determination of two metabolites of tribendimidine, deacylated amidantel and its acetylated metabolite in plasma, blood and dried blood spots. Journal of Pharmaceutical and Biomedical Analysis 105, pages 163-173.
Crossref
Crossref
Ashwin N. Ananthakrishnan, Mengmeng Du, Sonja I. Berndt, Hermann Brenner, Bette J. Caan, Graham Casey, Jenny Chang-Claude, David Duggan, Charles S. Fuchs, Steven Gallinger, Edward L. Giovannucci, Tabitha A. Harrison, Richard B. Hayes, Michael Hoffmeister, John L. Hopper, Lifang Hou, Li Hsu, Mark A. Jenkins, Peter Kraft, Jing Ma, Hongmei Nan, Polly A. Newcomb, Shuji Ogino, John D. Potter, Daniela Seminara, Martha L. Slattery, Mark Thornquist, Emily White, Kana Wu, Ulrike Peters & Andrew T. Chan. (2015) Red Meat Intake, NAT2, and Risk of Colorectal Cancer: A Pooled Analysis of 11 Studies. Cancer Epidemiology, Biomarkers & Prevention 24:1, pages 198-205.
Crossref
Crossref
Zhi-duo Hou, Zheng-yu Xiao, Yao Gong, Yu-ping Zhang & Qing Yu Zeng. (2014) Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine. BMC Pharmacology and Toxicology 15:1.
Crossref
Crossref
Joan Eilstein, Guillaume Léreaux, Natali Budimir, Georges Hussler, Simon Wilkinson & Daniel Duché. (2014) Comparison of xenobiotic metabolizing enzyme activities in ex vivo human skin and reconstructed human skin models from SkinEthic. Archives of Toxicology 88:9, pages 1681-1694.
Crossref
Crossref
S. J. Garcés-Eisele, B. Cedillo-Carvallo, V. Reyes-Núñez, L. Estrada-Marín, R. Vázquez-Pérez, M. Juárez-Calderón, M. O. Guzmán-García, A. Dueñas-González & A. Ruiz-Argüelles. (2014) Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. Journal of Clinical Pharmacy and Therapeutics 39:4, pages 368-375.
Crossref
Crossref
Farren B. S. Briggs, Brigid Acuna, Ling Shen, Patricia Ramsay, Hong Quach, Allan Bernstein, Kalliope H. Bellesis, Ingrid S. Kockum, Anna K. Hedström, Lars Alfredsson, Tomas Olsson, Catherine Schaefer & Lisa F. Barcellos. (2014) Smoking and Risk of Multiple Sclerosis. Epidemiology 25:4, pages 605-614.
Crossref
Crossref
Liang Zhang, Zhaolan Xiang, Rui Hao, Ru Li & Yi Zhu. (2013) N-acetyltransferase 2 genetic variants confer the susceptibility to head and neck carcinoma: evidence from 23 case–control studies. Tumor Biology 35:4, pages 3585-3595.
Crossref
Crossref
Liming Wang, Weifeng Tang, Suocheng Chen, Yangyong Sun, Yu Fan, Yijun Shi, Jingfeng Zhu, Xu Wang, Liang Zheng, Aizhong Shao, Guowen Ding, Chao Liu, Ruiping Liu, Jun Yin & Haiyong Gu. (2014) N-acetyltransferase 2 Polymorphisms and Risk of Esophageal Cancer in a Chinese Population. PLoS ONE 9:2, pages e87783.
Crossref
Crossref
Lizania Borges Spinasse, Adalberto Rezende SantosPhilip Noel Suffys, Elizabeth Silaid Muxfeldt & Gil Fernando Salles. (2014)
Different phenotypes of the
NAT2
gene influences hydralazine antihypertensive response in patients with resistant hypertension
. Pharmacogenomics 15:2, pages 169-178.
Crossref
Crossref
Theodora Tsirka, Sotiria Boukouvala, Bogos Agianian & Giannoulis Fakis. (2014) Polymorphism p.Val231Ile alters substrate selectivity of drug-metabolizing arylamine N-acetyltransferase 2 (NAT2) isoenzyme of rhesus macaque and human. Gene 536:1, pages 65-73.
Crossref
Crossref
B. Patillon, P. Luisi, E. S. Poloni, S. Boukouvala, P. Darlu, E. Genin & A. Sabbagh. (2014) A Homogenizing Process of Selection Has Maintained an “Ultra-Slow” Acetylation <em>NAT2</em> Variant in Humans. Human Biology 86:3, pages 185.
Crossref
Crossref
Lauren Walker, Vincent Yip & Munir Pirmohamed. 2014. Handbook of Pharmacogenomics and Stratified Medicine. Handbook of Pharmacogenomics and Stratified Medicine
405
435
.
Vickie S. Wilson, Nagalakshmi Keshava, Susan Hester, Deborah Segal, Weihsueh Chiu, Chad M. Thompson & Susan Y. Euling. (2013) Utilizing toxicogenomic data to understand chemical mechanism of action in risk assessment. Toxicology and Applied Pharmacology 271:3, pages 299-308.
Crossref
Crossref
Weihsueh A. Chiu, Susan Y. Euling, Cheryl Siegel Scott & Ravi P. Subramaniam. (2013) Approaches to advancing quantitative human health risk assessment of environmental chemicals in the post-genomic era. Toxicology and Applied Pharmacology 271:3, pages 309-323.
Crossref
Crossref
Wolfgang Sadee. (2013) Gene–Gene–Environment Interactions Between Drugs, Transporters, Receptors, and Metabolizing Enzymes: Statins, SLCO1B1, and CYP3A4 as an Example. Journal of Pharmaceutical Sciences 102:9, pages 2924-2929.
Crossref
Crossref
Jesse D. Troy, Joel L. Weissfeld, Brenda Diergaarde, Ada O. Youk, Shama C. Buch, Marjorie Romkes & Jennifer R. Grandis. (2013) Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer. Cancer Epidemiology 37:4, pages 505-511.
Crossref
Crossref
Nathalie K. Zgheib, Ashraf A. Shamseddine, Eddy Geryess, Arafat Tfayli, Ali Bazarbachi, Ziad Salem, Ali Shamseddine, Ali Taher & Nagi S. El-Saghir. (2013) Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 747-748, pages 40-47.
Crossref
Crossref
Arash Etemadi, Farhad Islami, David H. Phillips, Roger Godschalk, Asieh Golozar, Farin Kamangar, Akbar Fazel‐Tabar Malekshah, Akram Pourshams, Seerat Elahi, Farhad Ghojaghi, Paul T. Strickland, Philip R. Taylor, Paolo Boffetta, Christian C. Abnet, Sanford M. Dawsey, Reza Malekzadeh & Frederik J. van Schooten. (2012) Variation in PAH‐related DNA adduct levels among non‐smokers: The role of multiple genetic polymorphisms and nucleotide excision repair phenotype. International Journal of Cancer 132:12, pages 2738-2747.
Crossref
Crossref
Xiaotong Zhou, Zhiguo Ma, Dong Dong & Baojian Wu. (2013) Arylamine N-acetyltransferases: a structural perspective. British Journal of Pharmacology 169:4, pages 748-760.
Crossref
Crossref
Julián G Chamorro, Jorge P Castagnino, Rosa M Musella, Mabel Nogueras, Federico M Aranda, Ana Frías, Mabel Visca, Omar Aidar, Silvia Perés & Gabriela F de Larrañaga. (2013) Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. Journal of Gastroenterology and Hepatology 28:2, pages 323-328.
Crossref
Crossref
Lauren Zeise, Frederic Y. Bois, Weihsueh A. Chiu, Dale Hattis, Ivan Rusyn & Kathryn Z. Guyton. (2013) Addressing Human Variability in Next-Generation Human Health Risk Assessments of Environmental Chemicals. Environmental Health Perspectives 121:1, pages 23-31.
Crossref
Crossref
Xin Wang, Lei Cui, Nannan Zhou, Weiping Zhu, Rui Wang, Xuhong Qian & Yufang Xu. (2013) A highly selective and sensitive near-infrared fluorescence probe for arylamine N-acetyltransferase 2 in vitro and in vivo. Chemical Science 4:7, pages 2936.
Crossref
Crossref
WENLEI ZHUO, LIANG ZHANG, ZHIQUN QIU, LEI CAI, BO ZHU & ZHENGTANG CHEN. (2012) Association of NAT2 polymorphisms with risk of colorectal adenomas: Evidence from 3,197 cases and 4,681 controls. Experimental and Therapeutic Medicine 4:5, pages 895-900.
Crossref
Crossref
Alexander V. LyubimovBennett Ma & Michael L. Schrag. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
29
.
Jeremy M. Sharib, Jobin Cyrus, Andrew Horvai, Florette K. Gray Hazard, John Neuhaus, Katherine K. Matthay, Robert Goldsby, Neyssa Marina & Steven G. DuBois. (2012) Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma. Pediatric Blood & Cancer 59:4, pages 611-616.
Crossref
Crossref
Xian-Lu Zhuo, Jun-Jun Ling, Yan Zhou, Hou-Yu Zhao, Yu-Feng Song & Ying-Hui Tan. (2012) NAT2 polymorphisms with oral carcinoma susceptibility: a meta-analysis. Molecular Biology Reports 39:9, pages 8813-8819.
Crossref
Crossref
Jennifer J. Kiser, Rui Zhu, David Z. D'Argenio, Mark F. Cotton, Raziya Bobat, George D. McSherry, Shabir A. Madhi, Vincent J. Carey, Heiner I. Seifart, Cedric J. Werely & Courtney V. Fletcher. (2012) Isoniazid Pharmacokinetics, Pharmacodynamics, and Dosing in South African Infants. Therapeutic Drug Monitoring 34:4, pages 446-451.
Crossref
Crossref
Deepak Voora & Geoffrey S. Ginsburg. (2012) Clinical Application of Cardiovascular Pharmacogenetics. Journal of the American College of Cardiology 60:1, pages 9-20.
Crossref
Crossref
Helen McIlleron, Roxana Rustomjee, Mahnaz Vahedi, Thuli Mthiyane, Paolo Denti, Catherine Connolly, Wasima Rida, Alexander Pym, Peter J. Smith & Philip C. Onyebujoh. (2012) Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines. Antimicrobial Agents and Chemotherapy 56:6, pages 3232-3238.
Crossref
Crossref
Sheila Annie Peters. 2012. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations
161
181
.
Sheila Annie Peters. 2012. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations
383
399
.
Ibrahim A. Yassine, Loulou Kobeissi, Michel E. Jabbour & Hassan R. Dhaini. (2012)
N-Acetyltransferase 1 (
NAT1
) Genotype: A Risk Factor for Urinary Bladder Cancer in a Lebanese Population
. Journal of Oncology 2012, pages 1-10.
Crossref
Crossref
Lucia Taja-Chayeb, Aurora González-Fierro, Cristian Miguez-Muñoz, Catalina Trejo-Becerril, Erick de la Cruz-Hernandez, David Cantu, Jose A. Agundez, Silvia Vidal-Millan, Olga Gutierrez & Alfonso Dueñas-González. (2011) Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype–genotype correlation with the sulfamethazine test. Pharmacogenetics and Genomics 21:12, pages 894-901.
Crossref
Crossref
Weihsueh A. Chiu & Gary L. Ginsberg. (2011) Development and evaluation of a harmonized physiologically based pharmacokinetic (PBPK) model for perchloroethylene toxicokinetics in mice, rats, and humans. Toxicology and Applied Pharmacology 253:3, pages 203-234.
Crossref
Crossref
Marco A. RamosRosa E. MaresErick D. AvalosAnaid HernándezRogelio HernándezRodrigo LamedaAnalleli E. MalváezCarla A. RodríguezRosario Rodríguez. (2011)
Pharmacogenetic Screening of
N
-Acetyltransferase 2, Thiopurine
S
-Methyltransferase, and 5,10-Methylene-Tetrahydrofolate Reductase Polymorphisms in Northwestern Mexicans
. Genetic Testing and Molecular Biomarkers 15:5, pages 351-355.
Crossref
Crossref
Sabina Semiz, Tanja Dujic, Barbara Ostanek, Zelija Velija-Asimi, Besim Prnjavorac, Tamer Bego, Maja Malenica, Barbara Mlinar, Becir Heljic, Janja Marc & Adlija Causevic. (2011) Association of NAT2 Polymorphisms with Type 2 Diabetes in a Population from Bosnia and Herzegovina. Archives of Medical Research 42:4, pages 311-317.
Crossref
Crossref
W Sadee, D Wang, A C Papp, J K Pinsonneault, R M Smith, R A Moyer & A D Johnson. (2011) Pharmacogenomics of the RNA World: Structural RNA Polymorphisms in Drug Therapy. Clinical Pharmacology & Therapeutics 89:3, pages 355-365.
Crossref
Crossref
Chen Bing, Cao Xiaomeia & Li Jinhenga. (2011) Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects. Drug Metabolism and Drug Interactions 26:3.
Crossref
Crossref